Lumenis - OptiLIGHT - Dry Eye Medical Device Get latest price

OptiLIGHT is the first and only FDA-approved IPL (Intense Pulsed Light) device for the management of dry eye disease caused by Meibomian Gland Dysfunction (MGD). Developed by Lumenis, it employs patented Optimal Pulse Technology (OPT™) to deliver targeted, controlled, and comfortable light-based therapy to relieve symptoms and address the multifactorial nature of dry eye.

• Patented OPT™ handpiece for customised treatments along delicate facial contours.
• Ergonomic IPL handpiece with SapphireCool™ technology for wider, safer, and more comfortable treatment.
• Clinically validated treatment protocols embedded for safe and effective use.
• Opti-Tip for hygienic, safe, and optimal energy delivery to delicate areas.
• Visible results with each session taking only 15 minutes; typical course consists of 4 sessions.
• No significant downtime—possible minor redness post-treatment, resolving in hours.
• Design prioritises both patient safety and clinical efficacy.

• Reduces inflammatory mediators and abnormal blood vessels that perpetuate inflammation.
• Improves tear breakup time and decreases osmolarity of tears.
• Restores meibomian gland morphology and functionality.
• Reduces Demodex mite populations and bacterial load on eyelids.

• Approved for patients 22 years and older with moderate to severe dry eye due to MGD on Fitzpatrick skin types I–IV (AU & US), and I–V (EU).
• Contraindications include recent ocular or eyelid surgery, uncontrolled eye disorders, skin cancers or lesions in treatment area, certain infections and neurological disorders, photosensitive medications, recent radiation/chemotherapy, and a history of seizures, migraines, or herpes in treatment area.

• Common side effects: transient redness, mild discomfort, or swelling; rare risks include changes in skin pigmentation or texture, bruising and rare burns.
• Strict use guidelines must be followed; practitioner and patient safety ensured with protective eyewear and adherence to protocols.